- Home
- COCP vs CYCC Comparison
COCP vs CYCC Comparison
Compare COCP & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- CYCC
- Stock Information
- Founded
- COCP 2006
- CYCC 1992
- Country
- COCP United States
- CYCC Malaysia
- Employees
- COCP N/A
- CYCC N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- CYCC Health Care
- Exchange
- COCP Nasdaq
- CYCC Nasdaq
- Market Cap
- COCP 15.5M
- CYCC 17.5M
- IPO Year
- COCP N/A
- CYCC N/A
- Fundamental
- Price
- COCP $1.46
- CYCC $7.46
- Analyst Decision
- COCP Strong Buy
- CYCC
- Analyst Count
- COCP 1
- CYCC 0
- Target Price
- COCP $6.00
- CYCC N/A
- AVG Volume (30 Days)
- COCP 29.6K
- CYCC 105.8K
- Earning Date
- COCP 08-14-2025
- CYCC 08-13-2025
- Dividend Yield
- COCP N/A
- CYCC N/A
- EPS Growth
- COCP N/A
- CYCC N/A
- EPS
- COCP N/A
- CYCC N/A
- Revenue
- COCP N/A
- CYCC $10,000.00
- Revenue This Year
- COCP N/A
- CYCC $137.21
- Revenue Next Year
- COCP N/A
- CYCC N/A
- P/E Ratio
- COCP N/A
- CYCC N/A
- Revenue Growth
- COCP N/A
- CYCC N/A
- 52 Week Low
- COCP $1.12
- CYCC $3.08
- 52 Week High
- COCP $3.26
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- COCP 38.13
- CYCC 42.84
- Support Level
- COCP $1.37
- CYCC $7.30
- Resistance Level
- COCP $1.60
- CYCC $8.82
- Average True Range (ATR)
- COCP 0.09
- CYCC 0.69
- MACD
- COCP -0.01
- CYCC 0.05
- Stochastic Oscillator
- COCP 27.52
- CYCC 22.09
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.